125 patients experiencing unilateral peripheral neuropathic pain and allodynia were randomly assigned to either treatment with sativex, a delta-9-tetrahydrocannabinol and cannabidiol (THC:CBD) endocannabinoid system modulator, or placebo. Patient-reported pain and allodynia severity, as well as the incidence of adverse events, were assessed at baseline and 5-week follow up. Results demonstrated that sativex was effective in reducing pain and allodynia from baseline compared to placebo, but was associated with greater incidence of gastrointestinal adverse events.